Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer

By Choi Y.S.   Shim Y.M.   Kim J.   Kim K.  

European Journal of Cardio-Thoracic Surgery, Vol. 22, Iss. 5, 2002-11 ,pp. : 695-700

Elsevier

Access to resources Recommend Favorite

Prognostic factors in patients with resected pathologic (p-) T1-2N1M0 non-small cell lung cancer (NSCLC)

By Tanaka F.   Yanagihara K.   Otake Y.   Yamada T.   Shoji T.   Miyahara R.   Inui K.   Wada H.  

European Journal of Cardio-Thoracic Surgery, Vol. 19, Iss. 5, 2001-05 ,pp. : 555-561

Elsevier

Access to resources Recommend Favorite

Prognostic Model of Stage II Non-Small Cell Lung Cancer by a Discriminant Analysis of the Immunohistochemical Protein Expression

By Kohri Takayuki   Sugano Masayuki   Kawashima Osamu   Saito Ryusei   Sakurai Shinji   Sano Takaaki   Nakajima Takashi  

Surgery Today, Vol. 36, Iss. 12, 2006-12 ,pp. : 1039-1046

Springer Publishing Company

Access to resources Recommend Favorite

Advantage of post-operative oral administration of UFT (Tegafur and Uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC)

By Tanaka F.   Miyahara R.   Ohtake Y.   Yanagihara K.   Fukuse T.   Hitomi S.   Wada H.  

European Journal of Cardio-Thoracic Surgery, Vol. 14, Iss. 3, 1998-09 ,pp. : 256-262

Elsevier

Access to resources Recommend Favorite

Advantage of postoperative oral administration of UFT (Tegafur and Uracil) for completely resected p-Stage I-IIIa non-small cell lung cancer (NSCLC)

By Maggi G.   Ruffini E.  

European Journal of Cardio-Thoracic Surgery, Vol. 14, Iss. 3, 1998-09 ,pp. : 263-264

Elsevier

Access to resources Recommend Favorite